Comparison of preoperative serum neopterin, periostin, indoleamine 2,3-dioxygenase, YKL-40, and tenascin-C levels with current tumor markers for early-stage endometrial cancer

Basit Öğe Kaydı
dc.authoridMELEKOGLU, RAUF/0000-0001-7113-6691
dc.authoridbasak, nese/0000-0001-5566-8321;
dc.authorwosidMELEKOGLU, RAUF/AAF-1614-2019
dc.authorwosidbasak, nese/ABH-5495-2020
dc.authorwosidYaşar, Şeyma/ABI-8055-2020
dc.contributor.authorUnuvar, Songul
dc.contributor.authorMelekoglu, Rauf
dc.contributor.authorTurkmen, Nese B.
dc.contributor.authorYilmaz, Ercan
dc.contributor.authorYasar, Seyma
dc.contributor.authorYuce, Hande
dc.date.accessioned2024-08-04T20:49:25Z
dc.date.available2024-08-04T20:49:25Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: To compare the predictive value of serum levels of neopterin, periostin, YKL-40, tenascin-C (TNC), and indoleamine 2,3-dioxygenase (IDO) with current tumor markers for the primary diagnosis of early-stage endometrial cancer. Methods: A prospective cross-sectional study was conducted between January 2020 and November 2020. A total of 59 patients (38 women newly diagnosed with early-stage endometrial cancer [study group] and 21 women with benign endometrial pathologies [control group]) were enrolled. Blood samples were collected prior to surgery and underwent immunoassay analysis. Results: Carcinoembryonic antigen (CEA), periostin, and IDO levels were significantly higher in the study group than the control group (P = 0.008, P = 0.034, and P = 0.003, respectively). Receiver operating characteristic curve analysis revealed that IDO, periostin, and CEA were good predictors of early-stage endometrial cancer (AUC = 0.733, 95% CI, 0.602-0.840, P < 0.002; AUC = 0.668, 95% CI, 0.533-0.785, P = 0.018; and AUC = 0.709, 95% CI, 0.576-0.820, P = 0.002, respectively). Correlation analysis revealed no significant correlation of any biomarker with age or body mass index in either the control or study group. Conclusion: Serum CEA, periostin, and IDO levels were significantly higher in women with endometrial cancer than in those without cancer. These results may help identify new markers for diagnosing endometrial cancer.en_US
dc.identifier.doi10.1002/ijgo.13666
dc.identifier.endpage424en_US
dc.identifier.issn0020-7292
dc.identifier.issn1879-3479
dc.identifier.issue3en_US
dc.identifier.pmid33660848en_US
dc.identifier.scopus2-s2.0-85102931722en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage417en_US
dc.identifier.urihttps://doi.org/10.1002/ijgo.13666
dc.identifier.urihttps://hdl.handle.net/11616/99844
dc.identifier.volume155en_US
dc.identifier.wosWOS:000631925300001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Gynecology & Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectendometrial canceren_US
dc.subjectindoleamine 2,3-dioxygenaseen_US
dc.subjectneopterinen_US
dc.subjectperiostinen_US
dc.subjecttenascin-Cen_US
dc.subjecttumor biomarkersen_US
dc.subjectYKL-40en_US
dc.titleComparison of preoperative serum neopterin, periostin, indoleamine 2,3-dioxygenase, YKL-40, and tenascin-C levels with current tumor markers for early-stage endometrial canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu